Clinical Trial Update: Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

Phase II trial investigating romiplostim with danazol for patients with eltrombopag-resistant immune thrombocytopenia is ongoing (Phase II, status unknown).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Danazol (danazol)
• Romiplostim (romiplostim)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Immune Thrombocytopenia | Phase 2 | Status: UNKNOWN